Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab
{{output}}
Objectives: To compare the single-dose pharmacokinetics (PK), safety, and immunogenicity of the biosimilar infliximab (BOW015) to reference infliximab (rIFX) in healthy volunteers and to establish bioequivalence. ... ...
